Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment

Journal of B.U.ON.

Volumn 16, Issue 3, 2011, Pages 460-463

  Odabas, H ^a   Ozdemir, N ^a   Isik, Metin ^a   Abali, H ^b   Oksuzoglu, B ^a   Kos, T ^a   Civelek, B ^a   Babacan, A N ^a   Dogan, U ^a   Zengin, N ^a  

^a Division of Internal Medicine   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

FOLFIRI bevacizumab; Metastatic colorectal carcinoma; Second line chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; UFT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 80053979730     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rougier P, Lepere C. Second-line treatment of patients with metastatic colorectal cancer. Semin Oncol 2005; 32 (6 Suppl 9): 48-54.
2. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599. (Pubitemid 27441066)
3. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
4. Hurwitz H, Fehrenbacher, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
5. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786. (Pubitemid 350086481)
6. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-5334.
7. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
8. Sobrero A, Ackland S, Clarke S et al. Phase TV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009; 77: 113-119.
9. Kopetz S, Hoff PM, Morris JS et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010; 28: 453-459.
10. Ulrich-Pur H, Kornek GV, Fiebiger W et al. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001; 12: 1269-1272. (Pubitemid 32994756)
11. Stickel F, Jüngert B, Brueckl V et al. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anticancer Drugs 2003; 14: 745-749. (Pubitemid 37357700)
12. Recchia F, Saggio G, Nuzzo A et al. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Cancer 2004; 91: 1442-1446. (Pubitemid 39486345)
13. Souglakos J, Vardakis N, Androulakis N et al. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial. J BUON 2005; 10: 47-52. (Pubitemid 41319766)
14. Mabro M, Artru P, André T et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006; 94: 1287-1292.
15. Sørbye H, Berglund A, Tveit KM et al. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. Acta Oncol 2007: 46: 982-988. (Pubitemid 47537179)
16. Giantonio BJ, Catalano PJ, Meropol NJ et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544. (Pubitemid 46733080)
17. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007; 12: 356-361. (Pubitemid 46556802)
18. Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007; 13: 6231-6235.
19. Yildiz R, Buyukberber S, Uner A et al. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Invest 2010; 28: 33-37.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
21. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237. (Pubitemid 41095086)
22. Koyama M, Murata A, Kimura Y et al. Bevacizumab in combination with mFOLFOX or FOLFIRI for previously treated metastatic colorectal cancer. Gan To Kagaku Ryoho 2010; 37: 1069-1073.